Brain cancer is a group of diverse and rapidly growing malignancies that originate in the central nervous system (CNS) and have a poor prognosis. The complexity of brain structure and function makes brain cancer modeling extremely difficult, limiting pathological studies and therapeutic developments. Advancements in human pluripotent stem cell technology have opened a window of opportunity for brain cancer modeling, providing a wealth of customizable methods to simulate the disease in vitro. This is achieved with the advent of genome editing and genetic engineering technologies that can simulate germline and somatic mutations found in human brain tumors. This review investigates induced pluripotent stem cell (iPSC)-based approaches to model...
Glioblastoma (GB) is the most frequent and aggressive type of glioma. The lack of reliable GB models...
Many human neurological diseases are not currently curable and result in devastating neurologic sequ...
The high attrition rate in drug development processes calls for additional human-based model systems...
Summary: We have developed a cancer model of gliomas in human cerebral organoids that allows direct ...
Human brain development is an intricate process that involves closely timed coordination of cell pro...
Summary: The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of...
Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance to convent...
Glioblastoma, a grade IV astrocytoma, is regarded as the most aggressive primary brain tumour with a...
Many cellular models aimed at elucidating cancer biology do not recapitulate pathobiology including ...
Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance to convent...
Despite intensive research, glioblastoma multiforme remains one of the tumours of the central nervou...
International audienceGlioma tumour-initiating cells (GTICs) can originate upon the ă transformation...
Early onset diseases such as childhood malignancies and neurodevelopmental disorders have been intri...
Dysregulated, stem cell-like self-renewal has been implicated in glioma treatment resistance and tum...
There is an urgency for identifying effective therapies for glioblastoma (GBM), an incurable and let...
Glioblastoma (GB) is the most frequent and aggressive type of glioma. The lack of reliable GB models...
Many human neurological diseases are not currently curable and result in devastating neurologic sequ...
The high attrition rate in drug development processes calls for additional human-based model systems...
Summary: We have developed a cancer model of gliomas in human cerebral organoids that allows direct ...
Human brain development is an intricate process that involves closely timed coordination of cell pro...
Summary: The prognosis of patients with glioblastoma (GBM) remains dismal, with a median survival of...
Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance to convent...
Glioblastoma, a grade IV astrocytoma, is regarded as the most aggressive primary brain tumour with a...
Many cellular models aimed at elucidating cancer biology do not recapitulate pathobiology including ...
Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance to convent...
Despite intensive research, glioblastoma multiforme remains one of the tumours of the central nervou...
International audienceGlioma tumour-initiating cells (GTICs) can originate upon the ă transformation...
Early onset diseases such as childhood malignancies and neurodevelopmental disorders have been intri...
Dysregulated, stem cell-like self-renewal has been implicated in glioma treatment resistance and tum...
There is an urgency for identifying effective therapies for glioblastoma (GBM), an incurable and let...
Glioblastoma (GB) is the most frequent and aggressive type of glioma. The lack of reliable GB models...
Many human neurological diseases are not currently curable and result in devastating neurologic sequ...
The high attrition rate in drug development processes calls for additional human-based model systems...